Cover Image
市場調查報告書

腎功能衰竭:開發中產品分析

Renal Failure - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 251777
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
腎功能衰竭:開發中產品分析 Renal Failure - Pipeline Review, H2 2014
出版日期: 2014年08月25日 內容資訊: 英文 46 Pages
簡介

所謂腎功能衰竭是因腎臟過濾機能障礙引起的疾病。在急性腎臟損傷/障礙或是急性腎臟衰竭的情況下,會突發性急速發病。致病危險因子包含腎臟病、肝臟病、糖尿病、高血壓、心臟疾病及肥胖。腎功能衰竭的症狀有被稱為側腹痛的胸腔下部背痛,其他還有下肢腫脹、噁心·嘔吐,及混亂·不安、或是強烈睡意等。

本報告提供腎功能衰竭的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗各階段的產品概要,再加上主要企業簡介,藥物簡介等相關資料,有系統的資訊。

目錄

簡介

腎功能衰竭概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發中的產品:大學/研究機關別

治療藥的開發企業

  • Pathfinder Cell Therapy, Inc.
  • 3SBio Inc.
  • Virobay Inc.
  • Zyrnat Biotherapeutics SL
  • Liaoning Cheng Da Biotechnology Co., Ltd

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介(產品說明/作用機制/R&D進展)

暫停的計劃

中止開發的產品

產品開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5407IDB

Summary

Global Markets Direct's, 'Renal Failure - Pipeline Review, H2 2014', provides an overview of the Renal Failure's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Renal Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Failure and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Renal Failure
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Renal Failure and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Renal Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Renal Failure pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Renal Failure
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Renal Failure pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Renal Failure Overview
  • Therapeutics Development
    • Pipeline Products for Renal Failure - Overview
    • Pipeline Products for Renal Failure - Comparative Analysis
  • Renal Failure - Therapeutics under Development by Companies
  • Renal Failure - Therapeutics under Investigation by Universities/Institutes
  • Renal Failure - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Renal Failure - Products under Development by Companies
  • Renal Failure - Products under Investigation by Universities/Institutes
  • Renal Failure - Companies Involved in Therapeutics Development
    • Pathfinder Cell Therapy, Inc.
    • 3SBio Inc.
    • Yungjin Pharm Ind. Co., Ltd.
    • Virobay Inc.
    • High Point Pharmaceuticals, LLC
  • Renal Failure - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Vaccine For Hemmorrhagic Fever With Renal Syndrome - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptide to Activate AGTR1 for Cardiovascular, Metabolic Disorders, Immunology, Genito Urinary System And Sex Hormones - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pathfinder Cells - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZY-11 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VBY-X - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DJ-5 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HPP-971 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YHT-1808 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Ixac - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Renal Failure - Dormant Projects
  • Renal Failure - Discontinued Products
  • Renal Failure - Product Development Milestones
    • Featured News & Press Releases
      • Feb 05, 2013: La Jolla Pharma Receives Notice Of Allowance For Patent Covering Modified Pectin Compositions
      • Jul 24, 2012: BioCryst Pharma Announces Positive Results From Two Ulodesine Phase II Trials In Patients With Gout
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Renal Failure, H2 2014
  • Number of Products under Development for Renal Failure - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Renal Failure - Pipeline by Pathfinder Cell Therapy, Inc., H2 2014
  • Renal Failure - Pipeline by 3SBio Inc., H2 2014
  • Renal Failure - Pipeline by Yungjin Pharm Ind. Co., Ltd., H2 2014
  • Renal Failure - Pipeline by Virobay Inc., H2 2014
  • Renal Failure - Pipeline by High Point Pharmaceuticals, LLC, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Renal Failure - Dormant Projects, H2 2014
  • Renal Failure - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Renal Failure, H2 2014
  • Number of Products under Development for Renal Failure - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top